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Abstract: Candida albicans is a polymorphic fungus responsible for mucosal and skin infections. Candida
cells establish themselves into biofilm communities resistant to most currently available antifungal
agents. An increase of severe infections ensuing in fungal septic shock in elderly or immunosuppressed
patients, along with the emergence of drug-resistant strains, urge the need for the development of
alternative antifungal agents. In the search for novel antifungal drugs our laboratory demonstrated that
two human ribonucleases from the vertebrate-specific RNaseA superfamily, hRNase3 and hRNase7,
display a high anticandidal activity. In a previous work, we proved that the N-terminal region of the
RNases was sufficient to reproduce most of the parental protein bactericidal activity. Next, we explored
their potency against a fungal pathogen. Here, we have tested the N-terminal derived peptides that
correspond to the eight human canonical RNases (RN1-8) against planktonic cells and biofilms of
C. albicans. RN3 and RN7 peptides displayed the most potent inhibitory effect with a mechanism of
action characterized by cell-wall binding, membrane permeabilization and biofilm eradication activities.
Both peptides are able to eradicate planktonic and sessile cells, and to alter their gene expression,
reinforcing its role as a lead candidate to develop novel antifungal and antibiofilm therapies.
Keywords: antimicrobial peptides; Candida albicans; biofilms; antifungal activity; RNaseA superfamily
1. Introduction
Candida albicans is the most common fungal pathogen that threatens hospitalized and
immunocompromised patients. Together with candidiasis in skin and mucosal infections, fungal
septic shock cases are also reported in elderly or immunosuppressed patients [1]. Most of the serious
symptoms of candidiasis are associated with biofilm formation occurring on the surfaces of host
tissues and medical devices, enhancing C. albicans virulence and resistance. Moreover, the most
representative feature of Candida biofilms is its increasing tolerance to conventional antifungal therapy.
The protection of the biofilm embedded cells against noxious agents, such as antifungals and the
host immune system arsenal, favors the thriving of persister cells and hinders the treatment of
biofilm-associated infections [2,3]. It has been estimated that the eradication of biofilm communities
requires concentrations of antifungals 1000 times higher compared to their planktonic stage [4,5]. This
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fact drastically reduces the availability of antifungal drugs appropriate to tackle C. albicans biofilms.
Frequently, drug doses need to be increased over the safety level [2]. Moreover, we are currently
facing an increase in yeast pathogenesis along with the emergence of drug-resistant strains, urging the
need for innovation of new effective antifungal agents. Antimicrobial proteins and peptides (AMPs)
are considered one of the main ancestral host defense systems. Largely distributed throughout the
different organism tissues, AMPs play an essential role as part of the human innate immune system,
constantly protecting the body against microbial invasion and diseases [6–8]. Because of their wide
distribution, physicochemical features, biological activities and rapid antimicrobial action against
a broad spectrum of microbes, AMPs have recently attracted significant attention as encouraging
antibiotic candidates [9–13]. Furthermore, due to their direct action at the microbial membrane
and multifaceted intracellular killing mechanisms, the use of AMPs as antibiotics should reduce the
appearance of resistant pathogens, a scenario that has been favored by the abuse of conventional
antibiotics [14,15]. The emergence of resistance mechanisms associated with fungal infections has also
encouraged the characterization of natural host defense peptides as lead candidates for the design of
novel drugs. In particular, several synthetic AMPs were successfully tested against C. albicans [16].
Among the human peptides that participate in the host innate immunity against fungal infections,
we find cathelicidins, histatins and defensins, that combine direct action to the pathogen cell together
with indirect immune-modulation activities [17].
In our research group, we have explored the use of human secretory RNases as antimicrobial
agents against Gram-negative and Gram-positive bacteria [18]. Following structure-functional studies,
an RNase derived peptide was proposed as a novel antibiofilm agents against Gram-negative
bacteria [19,20]. Likewise, in the search for novel antifungal agents, we recently reported that
human antimicrobial RNases are also effective against C. albicans through a dual mode of action [21,22].
Interestingly, the fungicidal activity of the RNases is initiated by the binding to the pathogen cell
wall, followed by their translocation and intracellular targeting [21]. In previous attempts to define
the antimicrobial activity of the hRNases, we designed the derived peptides corresponding to the
N-terminal of all them. The results demonstrated that the main antimicrobial activities are retained at
the first 45 residues of the parental ribonucleases. A comparison between each N-terminal derived
peptide and the related parental protein confirmed that their abilities to disrupt model membranes and
inherent antimicrobial activities were retained [23–25]. In this work, we have explored the mechanism
of action of the 1–45 N-terminus peptides of human canonical RNases (hRNases) against Candida
planktonic cells and the action toward established and early-biofilms. The promising results place
hRNase-derived peptides in the spotlight as therapeutic lead compounds and reinforce the value of
our own innate immune response arsenal in the fight against fungal infections.
2. Results
2.1. Peptides Design and Physicochemical Characterization
The hRNase-derived peptides were designed, taking as reference the 1–45 segment in hRNase3
sequence, based on previous work in our laboratory that defined the protein minimal domain retaining
full antimicrobial properties against Gram-positive and –negative bacteria. The N-terminal residues
of the hRNases represent a conserved evolutionary region that retains the protein host-defense
properties [23–25]. Figure 1 and Table 1 summarizes the main physiochemical, structural and biological
properties of the selected peptides. The eight N-terminal peptides (RN1–8), comprising equivalent
structural regions of the human canonical RNases N-termini [residues 1–45 of hRNases 2, 6, 7 and
8; residues 1–48 of hRNases 1 and 4; and residues 1–47 of hRNase 5;] were selected for synthesis to
test their antimicrobial capabilities against C. albicans. In all cases, the peptides included the first two
α-helices, as well as the firstβ-strand from the parental protein. As previously, the two cysteine residues
present at the N-terminal region were replaced by isosteric serine residues [23,25]. Previous structural
analysis and predictive studies indicated that the peptides adopted an helix in a membrane-like
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environment [23] (Figure 1 and Figure S1). Complementarily, Lys/Arg RNase N-terminal derived
peptides were engineered for the two most active peptides (RN3 and RN7), which incorporate Arg to
Lys substitutions for RNase 3, and Lys to Arg substitutions for RNase 7, named as RN3K and RN7R
respectively [23]. The substitution of Arg versus Lys in peptide structures sought to increase the cell
penetration capacity, as reported previously [26,27]. It is noteworthy to underline the high pI and
degree of hydrophobicity of the peptides (Table 1), adopting an amphipathic structure (Figure S1) and
showing values within the standard range of most-known AMPs [28], which are considered essential
for their functional activity [29]. Table 1 also includes the relative estimated values for the antimicrobial
activity of the hRNase parental proteins, as referenced in our previous work [30].
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Figure 1. (A) Sequence alignment of hRNases. Conserved regions are boxed; highly conserved amino
acids are colored in white over a red background, whereas o erately conserved amino acids regions
are colored in red. The secondary structure of hRNas is layed as a r f rence on t p of the
alignment. The N-terminal antimicrobial domain is highlighted in blue and the agglutination-promoting
region in orange. (B) The tertiary structure of Eosinophil cationic protein (ECP), the N-terminal domain
is colored according to the antimicrobial (blue) and aggregation (orange) properties (PDB code
4A2O). Right hand: Model representation of RN3 1–45, the figure was performed by PEP-FOLD3
(http://mobyle.rpbs.univ-paris-diderot.fr/cgi-bin/portal.py#forms::PEP-FOLD3).
Int. J. Mol. Sci. 2019, 20, 4558 4 of 24
Table 1. Physicochemical and biological properties of the hRNase-derived peptides.
Peptide † Sequence Hydrophobicity pI K/R
Protein
Antimicrobial
Activity *
Cytotoxicity
(THP1) #
GIC50 (µM)
RN1 -KESRAKKFQRQHMDSDSSPSSSSTYSNQMMRRRNMTQGRSKPVNTFVH −1.575 11.40 4/6 n.r >50
RN2 KPPQFTWAQWFETQHINMTSQ-QSTNAMQVINNYQRRSKNQNTFLL −1.069 10.28 2/2 - >50
RN3 RPPQFTRAQWFAIQHISLNPP-RSTIAMRAINNYRWRSKNQNTFLR −0.764 11.88 1/7 +++
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2.2. Antifungal Activity against Planktonic Cells of hRNases Is Retained at the N-terminus
Previous work in our laboratory using C. albicans demonstrated a high antifungal activity for
hRNases 3 and 7 [21]. Here, we report the antifungal activity of the eight N-terminal peptides
corresponding to the eight human canonical RNases. First, the minimum fungicidal concentration
(MFC) and 50% inhibitory concentration against infective C. albicans was determined. MFC values are
summarized in Table 2. Five peptides (1, 3, 4, 6 and 7) were found active against C. albicans, with MFC
ranging from 0.6 to 4 µM, a range close to that observed for the previously tested hRNases [21]. On the
other hand, peptides 2, 5 and 8 were inactive. A comparison of the bactericidal and candidacidal
activities of hRNases (Tables 1 and 2) highlighted a positive correlation, confirming that the antimicrobial
activity is preserved at the N–terminus.
On the other hand, no significant cytotoxicity for human THP1 cells is observed for the peptides at
the highest tested concentration (50 µM) (Table 1). Likewise, previous characterization of the peptide
hemolytic activities [23] also confirmed that no significant toxicity is observed at more than 10x the
achieved fungicidal concentration. The peptides RN3K and RN7R were also tested in their antifungal
activities, but the concentrations to reach an antimicrobial activity were higher in relation to their
wild type peptide (Supplementary Table S1). In the same way, no differences were observed for the
respective cytotoxic activity of either Lys/Arg peptide variants on host cells (Table 1).
Table 2. Antifungal Activities of hRNases Peptides on C. albicans.
hRNase Peptide
MFC100 (µM)
IC50 (µM)Sabouraud Broth PBS
RN1 3.75 ± 0.50 3.75 ± 0.30 2.10 ± 0.20
RN2 >20 >20 >20
RN3 0.62 ± 0.20 0.62 ± 0.10 0.22 ± 0.05
RN4 4.00 ± 0.50 3.75 ± 0.20 1.80 ± 0.30
RN5 >20 >20 >20
RN6 2.00 ± 0.50 1.75 ± 0.30 1.80 ± 0.20
RN7 0.93 ± 0.20 0.93 ± 0.10 0.45 ± 0.10
RN8 >10 >10 >10
Minimal fungicidal concentration (MFC100) was determined as the lowest concentration of peptide that killed at
least 99.9% of the initial inoculum. Values were calculated by Colony Forming Unit (CFU) counting on plated Petri
dishes as described in the methodology. C. albicans cultures were treated with the proteins diluted in either the
Sabouraud nutrient growth media or in a phosphate saline buffer (PBS). Values for 50% Inhibition Concentration
(IC50) for planktonic fungal cells were determined using the Bactiter-Glo™ kit as detailed in the Materials and
Methods section. Values are given as mean ± SEM.
Another specific feature of the mechanism of action of some AMPs is the ability to agglutinate
bacteria, a property proposed to facilitate the removal of the infection focus. Considering that
hRNase3 and its N-terminal domain [31] displayed a significant bacterial agglutinating activity, we
also assayed the RNases 3 and 7 action on Candida cell cultures. Accordingly, we confirmed that
hRNase3 is able to agglutinate C. albicans but not hRNase7 when tested up to 20 µM, in accordance
with their respective bacterial and liposome agglutination activities [31,32]. Following up, in order to
check whether hRNase-derived peptides also share this property against C. albicans, their minimum
agglutinating activity (MAC) was determined. Surprisingly, all peptides showed cell agglutination
activity (MAC < 2 µM), indicating that the required features for yeast cells agglutination are shared by
all the hRNases N-terminus (see supplementary Table S2 and Figure S2). In any case, after incubation
of C. albicans cell cultures with the hRNase-derived peptides, the most significant agglutination was
observed for RN3 (<0.1 µM), as previously observed for Gram-negative bacteria [23]. In addition,
when comparing MAC results between C. albicans and E. coli, we also observed a positive correlation for
Int. J. Mol. Sci. 2019, 20, 4558 6 of 24
peptides RN3 and RN6, being the two more agglutinating peptides within the family [23]. Interestingly,
a comparison of the MAC values indicate a higher agglutinating activity for C. albicans in comparison to
bacteria, suggesting that the peptides should have a particularly high affinity for fungi wall components.
In previous works, we assayed hRNase3 interaction to different bacterial cell wall components such
as lipopolysaccharide (LPS) and peptidoglycans [32,33], as well as heterosaccharides present at the
eukaryote extracellular matrix [34–36]. Here, we have characterized the peptides’ affinity for the fungi
cell wall and associated mechanism of action.
2.3. The Antifungal Mechanism of hRNase-Derived Peptides Relies on Membrane and Cell Wall Interactions
As reported in our previous work on antimicrobial hRNases, one of the first steps to counteract the
bacterial growth relies on the protein cell wall binding and membrane destabilization activity [31,33].
In an effort to characterize the antifungal mechanism of hRNase-derived peptides (RN1-8), we assessed
their capacity to depolarize and permeabilize C. albicans cytoplasmic membrane. Results showed that
overall most of the peptides active against C. albicans displayed high membrane permeabilization
and depolarization values (Table 3). The data agrees with previous depolarization and leakage
values in both Gram-negative and Gram-positive bacteria species. Noteworthy, RN3, RN6 and RN7
peptides displayed 50% Effective Displacement (ED50)depolarization values about 0.5-0.6 µM, with a
maximum depolarization value at final incubation time for RN3. In relation to Candida membrane
permeabilization and percentage of cell survival, the same three peptides showed the most effective
permeabilization, with mortality percentages above 70% after 2 hours of cell culture incubation with the
peptides. For a better characterization of the mechanism, we compared the kinetics of the membrane
destabilization and killing process by hRNase-derived peptides (Table 3). Working at a selected peptide
concentration around the estimated MFC values (2 µM), the time to reach 50% effectivity was estimated.
RN3 showed the best values in terms of cell survival, depolarization and permeabilization, followed
by RN7 and RN6. Previously, RNase derived N-terminal peptides were reported to have the ability
to bind anionic liposomes and trigger the vesicles lysis [23]. Moreover, as it has been reported for
other AMPs [37], a positive correlation had been observed regarding the lytic activity of the parental
RNases in both synthetic lipid vesicles and bacterial cells [31,32,38]. The present study on C. albicans
cell culture corroborates that these peptides share the characteristic AMPs features, displaying an
unspecific antimicrobial activity against both prokaryotic [23] and eukaryotic pathogens.
Table 3. Cell Membrane Depolarization, Permeabilization and Antimicrobial Activities of hRNases
Peptides on C. albicans.
hRNase Peptide
Membrane Depolarization Membrane Permeabilization Cell Survival
ED50 (µM) Depolmax * Max. Perm. (AU) 1 Perm. (%) 2 % ¥
RN1 4.63 ± 0.70 65.2 ± 4.6 26.1 ± 0.4 8.3 ± 0.4 67 ± 1
RN2 3.63 ± 1.20 28.6 ± 5.7 45.2 ± 0.8 12.4 ± 0.2 72 ± 0.5
RN3 0.60 ± 0.40 100 ± 3.2 166 ± 2 73.2 ± 1 15 ± 2
RN4 3.58 ± 1.60 76.2 ± 4.8 117 ± 2 38.7 ± 0.1 65 ± 10
RN5 1.51 ± 0.10 39.1 ± 5.1 66.5 ± 0.6 21.8 ± 0.4 39 ± 0.5
RN6 0.62 ± 0.10 86.2 ± 5.2 135 ± 1 48.4 ± 0.8 26 ± 2
RN7 0.53 ± 0.18 71.5 ± 3.7 136 ± 0.4 53.9 ± 0.5 12 ± 1
RN8 0.15 ± 0.20 36.1 ± 4.4 33.4 ± 0.4 11.2 ± 0.2 28 ± 1
ED50 depolarization values were calculated with peptide concentrations from 0.1 to 5 µM. * Maximum fluorescence
value reached at the final incubation time with 2 µM of the peptides. Membrane depolarization and permeabilization
were performed using the membrane potential-sensitive DiSC3 fluorescent probe and Sytox® Green, respectively, as
described in the Materials and Methods section. Values are given as mean ± SEM. ¥ Survival percentage at final
incubation time (120 min) was evaluated using the Live/DeadR kit. 1 Arbitrary fluorescence unit (AU) values are
indicated for maximum membrane depolarization and permeabilization. 2 The calculated percentages refer to the
maximum values achieved at final incubation time (50 min), referred to the positive control (10 % of Triton X-100).
All values are averaged from three replicates of two independent experiments.
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On the other hand, cationic peptides can display a high binding affinity toward anionic polymeric
structures, such as the bacterial and fungal cell envelopes. Two main layers can be distinguished in the
C. albicans cell wall: an outer layer composed mainly of glycoproteins and an inner layer in which
polysaccharides predominate. These polysaccharides confer strength and favor the cell shape. Beta-1,3
glucan, β-1,6 glucan and chitin are the most common polysaccharides, comprising 40%, 20% and 2%
of the cell wall dry weight respectively [39]. In particular, β-1,3-Glucan, the major component of the
fungi cell wall, is also a key element of the biofilm extracellular matrix [40,41]. Here, we selected
hRNase3 and its N-terminal derived peptide as the most antimicrobial active member of the family,
to assess the binding ability to both C. albicans cells and the β-d-Glucan (linear β-1,3-d-Glucan and
branched d-Glucose 1,6 units). Results shown in Figure 2 confirm that hRNase3 and the RN3 peptide
are able to bind to the C. albicans cell wall, and that the binding percentage increases as a function of
the incubation time.
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Figure 2. Binding of hRNase3 pepti e t . l i ll (l ft els) and β-d-Glucans (right panels).
RNase A was taken as a negative control for cell an -d- l ca bi ding, respectively. C. albicans cells
and β-d-Glucan ere incubated at different time (15, 30 and 60 min) with the protein and RN3 peptide:
hRNase3(1–45). The supernatant soluble fractions were prepared as described in the Experimental
Procedures. Supernatant represents the soluble fraction, which contains the unbound protein/peptide.
15% and 18% SDS-PAGE were respectively used to separate the protein and peptide fractions. Protein
and peptide alone were also loaded to the gel as positive controls (+).
2.4. Nucleic Acids Binding of RN3 and RN7 the Potent Anticandidal Peptides
Considering our promising results obtained with the characterization of the peptides’ antifungal
activities and cell- wall binding abilities, we decided to analyze the action of the two most potent
antifungal peptides (RN3 and RN7) in their abilities to bind DNA. We also based our selection in
the physicochemical properties of these peptides that coul facilitate the nucleic acid binding ability.
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Our previous work has demonstrated the effective internalization of hRNases3 and 7 within C. albicans
cells [20]. Here, we have tested the peptides’ affinity to nucleic acids, as putative intracellular targets.
The in-vitro DNA binding ability was determined by monitoring the electrophoretic mobility of
plasmidic DNA on an agarose gel. Results indicated that RN3 and RN7 bind to the plasmid DNA
and retarded its gel migration in a concentration-dependent manner (Figure 3). Similar affinities for
DNA were observed for the RN3K and RN7R counterparts (Supplementary Figure S3). This fact
encouraged us to continue the exploration of the potential action of these peptides over Candida albicans’
expression pattern.
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Figure 3. Gel retardation assay. Binding DNA was assayed by the inhibitory effect of peptides on
migration of DNA. Different amounts of peptides were incubated with 200 ng of pET 28a plasmid DNA
in 10 µL of binding buffer at room temperature during 20 min and subjected to electrophoresis on a
1.0% agarose gel. The first lane corresponds to negative control without peptide and the following
lanes correspond to weight ratios peptide/DNA 2.5:1, 5:1, 10:1, 20:1 and 50:1 respectively.
2.5. Evaluation of the Activities of RN3 and RN7 Peptides against C. albicans Biofilms
In order to get further insight into the mechanism of action of RN3 and RN7 derived peptides
against C. albicans, we evaluate the efficaci s of t ese peptides t eradicate pre-established biofilms.
We measured the viability and the biofilm mass following peptide tre tment by r azurin reduction
and crystal violet staining. Additionally, we evaluated by confocal microscopy the biofilm viability
a over ll structure. Biofilms formation is often associated with antifungal resistance, as compared
to planktonic cells, and requires drug concentrations of bout 30–2000 times to achieve equivalent
reduction of the cell metabolic activity [42]. Here, we assayed the peptide concentrations corresponding
to 5, 10 and 20 x MFC fold. For RN3 and RN7 peptides, an average MFC value of 1 µM was taken as
a reference. For amphotericin B and colistin we took as an internal reference MFC values of 0.5 and
0.25 µM, respectively; as previously reported [43–45]. The antibiofilm activity of the hRNase-derived
peptides was assessed using PrestoBlueTM reduction assay, which enables quantitation of the number
of living cells in 24h-old biofilms after treatment. The antibiofilm activity of all peptides was compared
at an equivalent MFC fold concentration. As observed in Figure 4, RN3 and RN7 peptides significantly
reduced C. albicans viability and mass of biofilms cells, compared to results with the non-treated cells.
An effective reduction of the biofilm viability is already significant at 5 µM for both RN3 and RN7
peptides. The biofilm viability decreased to about 30% for the RN3 peptide at a concentration of 10 µM,
highlighting potent action against of the pre-established biofilms of C. albicans (Figure 4).
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Figure 4. Effect of peptides (RN3 and RN7), colistin and amphotericin B on stablished C. albicans
biofilms. (A). The viability of preformed biofilm was qu ntified by PrestoBlue dye after 24 h of
incubation with the corresponding treatment at 5×, 10× and 20×MFC ( eptide conc ntration 5, 10
a d 20 µM; amphotericin B 2.5, 5 and 10 µM nd colisti 1. 5, 2.5 and 5 µM). Fluorescence changes
were me sured at excitation/emission of 535-615 nm. (B) The biofilm was stained by crystal viol t, th n
the dye was solubilized in etha ol, its absorbance measured at 570 nm and the percentage of biofilm
reduction was compared to untreated wells co trol. All experiments were done in triplicate. Statistically
significant results were evaluated by ANOVA test, foll wed by Dunnett’s Multiple Comparison Test
(* p < 0.05 and ** p < 0.001).
Interestingly, RN3 peptide showed a similar activity to the one displayed by colistin. However,
the RN3 peptide did not achieve the antibiofil activity values registered for amphotericin B, which is
currently considered one of the most effective antifungal agents [44]. Unfortunately, the main problem
encountered in the clinical use of amphotericin B is its high cytotoxicity and limited pharmacological
application, due to its adverse side-effects, such as fever, vomiting, anemia and nephrotoxicity [46].
To visualize the antibiofilm action of RN3 and RN7 peptides, the pre-established biofilms were
incubated during 4h with 20 µM of each peptide. Amphotericin B was used as a control of inhibition.
Quantitative analysis by confocal microscopy was performed using Live/Dead staining to estimate
the percentage of cell mortality of the biofilm total population and generate a 3D representation of
the layer depth. Both peptides drastically reduced the C. albicans viability to about 20%, as quantified
by PI staining (Figure 5). Interestingly, the samples treated with the peptides, and RN3 in particular,
showed a morphological change from yeast to hyphae stage that was not observed in the control
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biofilm (Figure 5). The untreated biofilm control was composed of non-branched pseudo and yeast
forms. We can hypothesize that as a mechanism of defense against the anticandidal treatment, the
sessile cells within the biofilm try to evade the antimitotic action by hyphae formation, limiting thereby
the drug penetration into the biofilm.
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 10 of 24 
 
in the control biofilm (Figure 5). The untreated biofilm control was composed of non-branched 
pseudo and yeast forms. We can hypothesize that as a mechanism of defense against the anticandidal 
treatment, the sessile cells within the biofilm try to evade the antimitotic action by hyphae formation, 
limiting thereby the drug penetration into the biofilm. 
 
 
Figure 5. (A) Visualization by confocal microscopy of mature C. albicans biofilms treated with 20 μM 
of RN3, RN7 and amphotericin B. Live/Dead stain corresponds to green and red labelled cells, 
respectively. Right-up detailed zone in control and RN3 images correspond to the overlapping of 
SYTO9 and PI, showing an increment of hypha formation and reduction of hyphal-viability. (B) 3D 
reconstruction and projections using the IMARIS software® of control and treated biofilm with RN3 
peptide. The percentage of viability in the biofilm was reduced to 18% ± 5. Bars: 30 μm. 
2.6. Modulation of the Gene Expression Profile Related to Cell Wall Synthesis and Biofilm Formation in 
Planktonic Cells  
Following up, we investigated whether the peptide treatment could alter the gene expression 
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Figure 5. (A) Visualization by confocal microscopy of mature C. albicans biofilms treated with 20 µM of
RN3, RN7 and amphotericin B. Live/Dead stain corresponds to green and red labelled cells, respectively.
Right-up detailed zone in control and RN3 images correspond to the overlapping of SYTO9 and PI,
showing an increment of hypha formation and reduction of hyphal-viability. (B) 3D reconstruction and
projections using the IMARIS software® of control and treated biofilm with RN3 peptide. The percentage
of viability in the biofilm was reduced to 18% ± 5. Bars: 30 µm.
2.6. Modulation of the Gene Expression Profile Related to Cell Wall Synthesis and Biofilm Formation in
Planktonic Cells
Following up, we investigated whether the peptide treatment could alter the gene expression
profile of Candida cells. First, we evaluated by qRT-PCR selected genes related to common metabolic
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activities as protein synthesis, glycolysis or synthesis of β-glycan wall-component using ACTIN as
a housekeeping gene. The first approach to determinate the changes in the gene expression was
quantified in Candida planktonic cells using a peptide concentration of 0.5 µM during two hours
of incubation, at the same time the cell viability was monitored by ATP quantification in order to
maintain the cellular population at equal proportions (control and treated cells). The results showed
up-regulation of 18s and KRE6 expression after incubation with both RN3 and RN7 peptides (Figure 6).
High expression of 18s might respond to a cellular stress caused by the peptides addition. Interestingly,
the increase in the KRE6 expression, a gene that encodes for the synthesis of the cell wall β-glycan,
might reflect a defense mechanism against the peptide action.
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Figure 6. Gene expression profile in planktonic cells of C. albicans cells after treatment with 0.5 µM of
RN3 and RN7 during 120 min of incubation. The mean values are averaged from two independent
experiments performed in duplicates. Statistically significant results were evaluated by ANOVA
test, followed by Dunnett’s Multiple Comparison Test. Significant values are indicated respect to the
non-treated cells (** p < 0.001); all the values are normalized in respect to ACTIN expression.
Lastly, we evaluated the effect of the RN3 and RN7 peptides on the expression of some genes
related to the biofilm formation. The potential molecular mechanism behind the ability of these
RNase derived peptides to prevent the growth of C. albicans biofilms was studied in a culture of
sessile cells exposed to 10 µM of each peptide during 24 h of incubation (Figure 7). We selected genes
involved in the early stage of hyphal formation, biofilm adhesion process (ALS3), expression of hyphal
transcriptional regulators in the cAMP-dependent protein kinase pathway (CYR1 and EFG1) and
production of the extracellular matrix (ADH5, CSH1, GSC1 and ZAP1). Following the incubation of
C. albicans cultures with both peptides we observed the down-regulation in many genes related to the
biofilm formation. Our results demonstrated suppression in the expression level of the hyphae-specific
gene that encodes for surface adhesins (ALS3) and the CYR1 and EFG1 transcriptional regulation
genes. ALS3 is a downstream component of the cAMP-PKA pathway and is positively regulated by
EFG1. Finally, the expression levels of genes involved in the extracellular matrix production were also
modulated following both peptides’ incubation. After RN3 incubation, the expression level of ADH5,
GSC1 and ZAP1 were down-regulated, with the exception of the CSH1 gene, which was up-regulated.
A similar pattern was displayed after incubation with RN7, except for the GSC1 and CSH1 genes, that
did not show any significant change. The results suggest that both RN3 and RN7 peptides inhibition of
the growth of C. albicans is partly mediated by the cAMP dependent kinase signaling pathway although
future work would be necessary to identify the specific altered pathways. The results also indicate
that the hRNase derived peptides treatment can also affect the biofilm formation by reducing the
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levels of adhesion proteins, interfering with hyphae formation and hindering the proper production of
extracellular matrix components, which are essential for biofilm formation.Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 12 of 24 
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carry out a host defense function [23]. Structural comparison of the structure of the hRNase3 N-
Figure 7. Quantitative RT-PCR analysis of C. albicans biofilm-related genes after 10 µM of RN3 and
RN7 treatment. C. albicans biofilms, at early stage of development (90 min), were incubated in the
presence or absence of both hRNase-derived peptides during 24 h, and then assessed by qPCR analysis.
The relative levels of gene expression are presented as fold changes in peptide-treated groups (RN3
peptide in dark grey and RN7 peptide in light grey) with respect to the untreated controls in black.
All gene transcript levels were normalized against ACT1 gene expression (pointed line). Statistically
significant results were evaluated by ANOVA test, followed by Dunnett’s Multiple Comparison Test.
* p < 0.001 indicates significant differences between peptide- treated and control groups.
3. Discussion
A high number of antimicrobial peptides have been proposed as alternative antibiotics to
combat microbial resistance. In contrast, there is still a scarce availability of peptide-based antifungal
drugs [2,47] and only very few are in clinical trial [11,48,49]. The virulence of C. albicans is mostly
associated with its ability to adhere to the host exposed surfaces and establish organized biofilms
communities, which are hard to eradicate. Noteworthy, Andes and coworkers observed the presence
of host proteins within the extracellular matrix of fungal biofilms, with an abundance of leukocyte
byproducts [50]. Indeed, proteins from our innate immune system embody the principal source of lead
candidates to develop novel antimicrobial agents. Within this context, our laboratory has explored
the antimicrobial mechanisms of action of the hRNases secreted by innate cells [22,51,52]. Several
members of the vertebrate-specific RNase A superfamily have shown antimicrobial features apparently
unrelated to their catalytic activity [30,53,54]. In an attempt to deepen the understanding of their
biological role it has been proposed that RNases might have emerged as a host-defense family in
vertebrate evolution [22,55,56].. Our previous studies on RNase A family members have revealed that
the antimicrobial activity is retained by their N-terminal-derived peptides [19,20,23,24]. In particular,
the action of the N-terminus of hRNase3 was characterized against Gram-positive and Gram-negative
bacteria. The protein 1-45 segment includes the first two α-helices from the parental protein, and
NMR studies indicate that the in-solution peptide adopts a unique extended alpha-helix [25,34]
(Figure 1B and Supplementary Figure S1). Figure 1B illustrates the helices α1 and α2 of the native
ECP and the key residues implicated in antimicrobial and aggregation activities. Complementarily,
Supplementary Figure S1 shows how the helical secondary structure would provide to the N-termini
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peptide a characteristic amphipathic nature. A comparative evolutionary study across vertebrate
RNases lineages suggested that the N-terminal region has been conserved to carry out a host defense
function [23]. Structural comparison of the structure of the hRNase3 N-terminus solved by NMR [34]
and the comparative CD analysis of the eight hRNases respective peptides indicated that without
sharing a high sequence identity, all the peptides adopt an equivalent structure [23]. Noteworthy, as
reported for many other AMPs, the eight peptides were mostly unstructured when free in an aqueous
solution and increased their alpha-helical content in the presence of a membrane like environment [23].
In order to expand knowledge of the mechanism of action of hRNases against C. albicans, which
was observed to take place by a dual mode [21], we aimed here to characterize the antifungal properties
of the hRNase derived N-terminal peptides. This comparative study of the N-terminal region of the
eight human hRNases against an eukaryotic pathogen such as C. albicans, has allowed us to deepen
in the mechanism of action of these proteins. The present results corroborate that the antimicrobial
activity of hRNases against fungi is also preserved at their N-terminal domain. The data reveal
a high antifungal activity, with MFC values at sub micromolar range for most tested derivative
peptides, being the RNase N-terminal derived peptides 3, 6 and 7 the most effective ones (Table 2).
These results are in agreement with previous studies where the parental proteins were tested against
C. albicans [21] and the derivative peptides assayed against different Gram-negative/Gram-positive
bacterial species [23,24,32,57]. In addition, the current data using C. albicans reinforce the correlation
between the peptide antimicrobial mechanism of action and the respective depolarization and
membrane permeabilization activities displayed by the eight parental RNase peptides, in agreement
with previous results [23].
Another specific feature of the N-terminal peptides is the cell agglutinating ability, proposed as a
mechanism to restrain the pathogens at the infection focus [54,58]. Previous studies highlighted the
bacterial agglutination for both hRNase3 and its N-terminal peptide [23,54,59]. Interestingly, higher
agglutination activities are observed for Candida cells in comparison to the tested Gram-negative
bacteria [23,59]. In particular, an outstanding high activity is observed here for the RN3 peptide.
Previous work identified aggregation prone domains at the N-terminus of RNases, showing a correlation
between positive agglutination values and the sequences aggregation propensity [23,54]. Besides,
the bacteria cell agglutination was also observed to be enhanced by the LPS interaction [58]. We report
here positive binding of hRNase3 and its derived peptide for both Candida cells and their main cell
wall component (Figure 2). Further work is to be carried out to evaluate the distinct binding affinities
toward the fungi cell wall patterns.
Additionally, peptides corresponding to Arg to Lys and Lys to Arg substitutions for the N-terminal
RNase 3 and 7 homologues were evaluated in order to check the contribution of Arg/Lys enrichment in
the peptide antipathogen selectivity (Figure 1). There is evidence in the literature about the importance
of some residues that favors endocytosis. It has been suggested that the quantity of Arg and Lys
residues, as well as their ratio and distribution, are essential in some AMPs and cell penetrating peptides
(CPPs) for cellular uptake [60]. Our previous work on hRNases antifungal activity demonstrated the
ability of hRNases 3 and 7 to internalize within C. albicans cells [21]. Interestingly, Arg content in
peptides is reported to facilitate the mammalian cellular uptake and improve their cytotoxic activity.
However, not only the cationic residue composition of peptides was found to be imperative, but also
the primary and secondary structures of the peptides have a high impact in the effectiveness of AMPs to
cross eukaryotic membranes and target intracellular dwelling pathogens [61]. In our case, the RNases3
and 7 Arg/Lys analogs (RN3K and RN7R) were less effective against C. albicans than their respective
reference peptides (Supplementary Table S1). On the other hand, no significant changes were observed
when the analog peptides were assayed in Gram-negative and Gram-positive bacterial cells [23].
Cationic antimicrobial peptides have attracted interest due to their high binding affinity to cell
anionic polymers, and nucleic acids in particular [62–64]. Interestingly, our results showed that the
most active antimicrobial peptides, RN3 and RN7, have a high binding affinity to DNA. However,
even though, the RN3K and RN7R peptides retain or even increase the positive net charge (Table 1),
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their DNA binding affinity is not enhanced (Figure 3 and Supplementary Figure S3). Likewise,
as commented above, no improvement of the antifungal activity of the peptide variants was observed
(Supplementary Table S2). Therefore, our data indicate that other structural determinants of the
peptides are required for their optimal overall performance. In any case, no significant alteration is
predicted for the overall helical content and nucleotide binding regions of Lys and Arg peptide variants
(Supplementary Figure S4).
To complement this work, we have explored the peptides’ ability to alter the C. albicans gene
expression profile. First, we monitored the expression pattern of selected representative genes related
to the overall cell metabolism and synthesis of cell wall components (GAPDH, 18s and KRE6) in
planktonic cells after peptide incubation for two hours. Interestingly, we observed an up-regulation
of the 18s subunit and KRE6 gene expression (Figure 6). Our results are in accordance with studies
reporting changes in the profile expression of C. albicans in response to other AMPs, such as LL-37 or
MAF-1A peptides [65]. The authors observed an induced expression of genes related to the Candida
cell wall synthesis and anti-oxidative stress [66]. The up-regulation on the expression level of KRE6
demonstrates a possible activation of the polysaccharide synthesis pathway to maintain cell wall
integrity and morphogenesis after the incubation with RN3 and RN7 (Figure 6), as reported previously
for other antimicrobial peptides [65]. One putative target of hRNase peptides might be a main cell wall
component, such as the β-glucan polymer. Therefore, we decided to explore whether the RN3 and
RN7 peptides could halt the growth and formation of Candida biofilms, as has been reported for other
AMPs [67,68].
It is worth stressing that growth of C. albicans biofilm communities within intravenous lines
and medical devices poses a serious clinical challenge. In particular, a high resistance to common
antibiotics is reinforced by the presence of quorum-sensing molecules that play an important role in
the biofilm formation, the release of virulence factors and the protection conferred by the extracellular
matrix [5,42,69]. Unfortunately, despite the advances in antimicrobial therapy, Candida biofilms remain
a challenge because biofilm embedded cells are tolerant towards most conventional antimycotics and
there are only few novel agents that can be used to treat biofilm-related infections. To date, only
miconazole, caspofungin, anidulafungin and liposomal formulations of amphotericin B are used to
effectively treat these infections [44,45]. However, due to serious side effects [46,70] there is a need
to identify novel antibiofilm compounds. Besides, current antifungal drugs have few specific targets
(i.e., ergosterol biosynthesis and 1,3-β-d-glucan synthesis), and it is widely agreed that antifungal
drugs with new mechanisms of action are needed [71]. An appropriate alternative relies on cationic
peptides, which establish electrostatic interactions to anionic phospholipids in fungal membranes, such
as phosphatidylserine and phosphatidylinositol, or to wall components, such as mannoproteins [72–74].
We find seldom examples of AMPs with antifungal activity, such as LL37, histatin5, the N-terminus
of human lactoferrin or the KP killer peptide [75–77]. Frequently, the antimicrobial peptides are
merely working as coadjuvants and require the complementary action of other antifungal agents [78].
Encouragingly, the hRNase peptides were able to eradicate C. albicans biofilms at a low micromolar
concentration (Figure 4). Moreover, we also found out that hRNase derived peptides are able to modify
the expression of genes involved in hypha growth, biofilm formation and extracellular matrix synthesis.
In addition, confocal microscopy analysis revealed that the treatment with the peptides RN3 and RN7
drastically reduces the biofilm viability to about 20%, altering the morphology of the mature biofilm
structure (Figure 5). The principal virulence of C. albicans relies on its ability to alternate between yeast
and hyphal form and generate a biofilm structure. As described above, the RN3 and RN7 peptides are
not only able to remove pre-formed biofilms, but also to alter the expression of genes related to the
biofilm formation. Upon RN3 and RN7 peptides treatment we observed the down-regulation of key
genes involved in the different stages of biofilm development (ALS3, CYR1, EFG1, ADH5 and ZAP1)
(Figure 7), with the exception of the CSH1 gene, which was upregulated after treatment with RN7.
The up-regulation of CSH1 expression was also reported in C. albicans biofilms exposed to peptide
KP [75]. These changes in the expression level of genes involved in biofilm formation corroborate
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that hRNase derived peptides act in multiples stages to prevent biofilm formation. The suppression
of the expression levels of some genes related to cAMP-PKA kinase pathways implicated in hyphal
formation-, such as CYR1 and EFG1, might indicate a potential target of interest of hRNase derived
peptides; however, further studies will be necessary to fully understand their mechanism of action.
On the other hand, removal of biofilms in vivo, is reported for salivary agglutinin and histatin
and can be facilitated by the peptide binding to the cell polysaccharide external layer and cell
agglutination [79]. Results with salivary histatins in animal models are promising and the antifungal
peptide is proposed for topical therapy for oral candidiasis [79]. A shorter version of histatin 5 is
currently in clinical trials. The mannose binding protein is a lectin also displaying a high affinity
for candida wall that can induce the yeast cells agglutination with proved efficacy in a murine
model [80–82]. No other examples of antimicrobial peptides endowed with an agglutinating activity
for Candida cells are found in the literature. Therefore, our present results highlight the multiples
targets of action of hRNase-derived peptides toward C. albicans cells and their potentiality. In particular,
the RN3 peptide combines high agglutination and antibiofilm activities. Novel peptide analogues
have been recently designed to enhance the peptide stability and resistance to proteases in vivo.
Further work is currently ongoing to ensure the peptide druggability before considering any potential
therapeutic application.
4. Materials and Methods
4.1. Peptide Synthesis
Peptides were synthesized as previously described [23]. Fmoc-protected amino acids and
hexafluorophosphate benzotriazole tetramethyl uronium (HBTU) were obtained from Iris Biotech.
Fmoc-Rink-amide (MBHA) resin was from Novabiochem. HPLC-grade acetonitrile (ACN)
and peptide-synthesis-grade dimethylformamide (DMF), N,Ndi-isopropylethylamine (DIEA) and
trifluoroacetic acid (TFA) were from Carlo Erba-SDS. Solid-phase peptide synthesis was done by
Fmoc-based chemistry on Fmoc-Rink-amide (MBHA) resin (0.1 mmol) in a model 433 synthesizer
(Applied Biosystems) running FastMoc protocols. Couplings used an 8-fold molar excess each of
Fmoc-amino acid and HBTU and a 16-fold molar excess of DIEA. Side chains of trifunctional residues
were protected with t-butyl (aspartate, glutamate, serine, threonine and tyrosine), t-butyloxycarbonyl
(lysine and tryptophan), 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (arginine) and trityl
(asparagine, glutamine and histidine) groups. After chain assembly, full deprotection and cleavage
were carried out with TFA/water/tri-isopropylsilane (95:2.5:2.5, by vol.) for 90 min at room temperature
(25 ◦C). Peptides were isolated by precipitation with ice-cold diethyl ether and separated by
centrifugation (3000× g for 20 min at 4 ◦C), dissolved in 0.1 M acetic acid, and freeze-dried. Analytical
reversed-phase HPLC was performed on a Luna C18 column (4.6 mm × 50 mm, 3 µm; Phenomenex).
Linear 5–60% gradients of solvent B (0.036% TFA in ACN) into solvent A (0.045% TFA in water) were
used for elution at a flow rate of 1 mL/min and with UV detection at 220 nm. Preparative HPLC
runs were performed on a Luna C18 column (21.2 mm × 250 mm, 10 µm; Phenomenex), using linear
gradients of solvent B (0.1% in ACN) into solvent A (0.1%TFA in water), as required, with a flow rate
of 25 mL/min. MALDI–TOF mass spectra were recorded in the reflector or linear mode in a Voyager
DE-STR workstation (Applied biosystems) using an α-hydroxycinnamic acid matrix. Fractions of
adequate (>90%) HPLC homogeneity and with the expected mass (supplementary Figures S5 and S6)
were pooled and freeze-dried for subsequent experiments.
4.2. C. albicans Growth Conditions
C. albicans (ATCC 90028) cells were stored at −80 ◦C (15% glycerol). After thawing, cells were
incubated overnight with agitation at 30 ◦C in Sabouraud Dextrose broth (Sigma S3306). Before each
assay, cells were sub-cultured for 2–3 h to yield a mid-logarithmic phase culture. For the biofilms
formation assay C. albicans cells were cultured in RPMI-1640 medium.
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4.3. Minimum Fungicidal Concentration
C. albicans was cultured overnight in Sabouraud Dextrose broth at 30 ◦C, sub-cultured the next
day in fresh media and grown to an optical density of 0.4 at 592 nm (mid log-phase). Cells were
washed twice and diluted to ~2 × 105 cells/mL. Peptides serially diluted were added to the cells from
20 to 0.1 µM final concentration. C. albicans was incubated at 30 ◦C during 4h in Sabouraud nutrient
broth or PBS. Following, the samples were plated onto Sabouraud Petri dishes and incubated at 30 ◦C
overnight. Antifungal activity was expressed as the MFC, defined as the lowest peptide concentration
required for more than 99% of microorganism killing. MFC of each peptide was determined from two
independent experiments performed in triplicate for each concentration.
4.4. Minimal Agglutination Activity (MAC)
C. albicans cells were grown at 30 ◦C to an OD592 of 1.0, diluted 10 times, centrifuged at 5000× g
for 2 min, and resuspended in 1× PBS. An aliquot of 100 µL of the cellular suspension was treated with
increasing peptide concentrations (from 0.01 to 20 µM) and incubated at 30 ◦C for 1 h. The aggregation
behavior was observed by visual inspection, and the agglutinating activity is expressed as the minimum
agglutinating concentration of the sample tested, as previously described [58]. Images were taken
using a 50× stereoscope microscope.
4.5. Cell Viability Assay
Cell viability of C. albicans was assayed using the BacTiter-Glo™ Microbial Cell Viability kit
(Promega), which measures the number of viable cells, by ATP quantification. ATP, as an indicator
of metabolically active cells, is indirectly measured by a coupled luminescence detection assay.
The luminescent signal is proportional to the amount of ATP required for the conversion of luciferin
into oxyluciferin in the presence of luciferase. An overnight culture of C. albicans was used to inoculate
fresh Sabouraud liquid culture, and logarithmic phase culture was grown to an OD592 of 0.2. RNase
derived N-terminal peptides were added to 0.1 mL of cell culture at a final concentration from 0.025 to
20 µM. The C. albicans viability was followed after 4 h of incubation at 30 ◦C. 50 µL of incubation culture
were mixed with 50 µL of BacTiter-GloTM reagent in a microtiter plate following the manufacturer
instructions and incubated at room temperature for 10 min. Luminiscence was read on a Victor3 plate
reader (PerkinElmer, Waltham, MA, USA) with a 1-s integration time. IC50 values were calculated by
fitting the data to a dose-response curve.
4.6. Cell Survival Assay
C. albicans viability assay was performed using the Live⁄Dead® microbial viability kit as previously
described [32]. Candida strain was grown at 30 ◦C to ~5 × 106 cells/mL, centrifuged at 5000× g for
5 min and resuspended in a 0.85% NaCl solution, in accordance with the manufacturer instructions.
C. albicans cell culture was stained using a SYTO®9/propidium iodide 1:1 mixture. SYTO9/propidium
iodide staining allowed us to monitor both the candidal viability in planktonic cell cultures and within
the biofilm, as the SYTO9 dye is able to permeate the cell membrane and stain the nucleic acid of viable
cells; whereas, when the cell membrane is damaged, propidium iodide can diffuse into the cell and
displace SYTO9. The method allows the labelling of intact viable cells and membrane compromised
cells, which are labelled in green and red respectively, referred to as live and dead cells. The viability
kinetics were monitored using a Cary Eclipse Spectrofluorimeter (Varian Inc., Palo Alto, CA, USA).
Cell viability profiles were registered after adding from 1 to 5 µM of final peptide concentration.
To calculate the cell viability, the fluorescence in the range of 510–540 nm and 620–650 nm were
integrated to obtain the SYTO®9 (live cell) and the propidium iodide (dead cell) signals respectively.
Then, the percentage of live bacteria was represented as a function of time.
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4.7. Cell Membrane Depolarization Assay
Membrane depolarization was assayed by monitoring the DiSC3 fluorescence intensity change in
response to changes in transmembrane potential as described previously [33]. C. albicans cells were
grown at 30 ◦C to the mid-exponential (OD592~0.4) and resuspended in 5 mM Hepes-KOH, 20 mM
glucose and 100 mM KCl at pH 7.2. DiSC3 was added to a final concentration of 0.4 µM. Changes in
the fluorescence for alteration of the cell plasma membrane potential were continuously monitored at
20 ◦C at an excitation wavelength of 620 nm and an emission wavelength of 670 nm. When the dye
uptake was maximal, as indicated by a stable reduction in the fluorescence as a result of quenching
of the accumulated dye in the membrane interior, protein in 5 mM Hepes-KOH buffer at pH 7.2
was added at a final peptide concentration from 1 to 5 µM and incubated for 50 min, to calculate
the ED50 concentration. Maximum depolarization was calculated when the fluorescence signal was
fully stabilized, and the depolarization percentage was calculated taking Triton X-100 at 10% as a
maximum reference value. The time required to reach a stabilized maximum fluorescence reading was
recorded for each condition, and the time required to achieve half of total membrane depolarization
was estimated from the nonlinear regression curve. All conditions were assayed in duplicate.
4.8. Cell Membrane Permeabilization Activity
Membrane permeabilization was evaluated by using the Sytox® Green uptake assay. Sytox®Green
is a cationic cyanine dye which is unable to cross the membrane. When cells’ plasma membrane
integrity is compromised, the dye enters into the cell, binding to DNA and triggering a large increase
of the fluorescence signal. For Sytox® Green assays, C. albicans cells were grown to mid-exponential
growth phase at 30 ◦C and then centrifuged, washed, and resuspended in PBS. Cell suspensions in PBS
(~2 × 106 cells/mL) were incubated with 1 µM Sytox® Green for 15 min in the dark prior to the influx
assay. At 2 to 4 min after initiating data collection, proteins at 1 and 5 µM final concentration were
added to the cell suspension, and the increase in Sytox® Green fluorescence was measured (excitation
wavelength at 485 nm and emission at 520 nm) for 50 min in a Cary Eclipse spectrofluorimeter. Fungal
cell lysis with 10% Triton X-100 was taken as the maximum fluorescence reference value.
4.9. Cell Binding Assay
C. albicans was cultured overnight in Sabouraud Dextrose broth at 30 ◦C, sub-cultured the next
day and grown to an optical density of 0.4 at 592 nm (mid log-phase). Cells were washed twice
in PBS and adjusted to 2 × 106 cells/mL. Cells and yeast β-d-Glucan (0.4 mg/mL) (Sigma) were
respectively incubated in 100 µL of PBS at 30 ◦C with proteins and peptides at 1 µM final concentration
during different periods of time up to 1 h. Following, the samples were centrifuged at 12,000× g.
The supernatant samples were concentrated, and the presence of the proteins and peptides was checked
by 15–18% SDS-PAGE and Coomassie Blue staining. Reference protein controls were treated following
the same protocol in the absence of cells.
4.10. DNA Binding Assay
Gel retardation experiments were performed following an adaptation of a previously described
protocol [83,84]. Briefly, aliquots of 300 ng of the plasmidic DNA (pET 28a) and increasing concentrations
of peptides were mixed in 10 µL of binding buffer consisting of 5% glycerol, 10 mM Tris HCl (pH 8.0),
1 mM EDTA, 20 mM KCl, and 50 mg/mL BSA and incubated at room temperature for 20 min. Aliquots
of each reaction were separated by electrophoresis on 1% agarose gels followed by ethidium bromide
staining. The peptide-to-DNA weight ratios were 0:1, 2.5:1, 5:1, 10:1, 20:1 and 50:1 respectively. Gel
retardation was visualized under UV illumination and recorded using gel Molecular Imager Gel
Doc XRS.
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4.11. Gene Expression Analysis
C. albicans gene expression of proteins implicated in common metabolic pathways was evaluated
following incubation with 0.5 µM concentrations of RN3 and RN7 at 30 ◦C. The protein expression levels
of 18s ribosomal RNA, Glyceraldehyde 3-phospate dehydrogenase (GAPDH) and KRE6 enzyme were
examined. KRE6 enzyme participates in the synthesis of β-1,6-glucan ramifications to the β-1,3-glucan
chain and provides a tight mesh structure to the cell wall. Total RNA was extracted using a mirVana™
Isolation Kit. C. albicans cell cultures (3 mL) at log-phase (OD592 of 0.2) were incubated with the
peptides during 2 h. After incubation, cells were sedimented and resuspended in lysis buffer, 10%
SDS and Phenol:Chloroform: isoamyl alcohol (IAA) and mixed with zirconia beads. RNA isolation
was done according to manufacturer’s instructions. The amount of RNA extracted was quantified
using a NanoDrop 2000 spectrophotometer (Thermo Scientific, USA). A yield of about 500 ng/µL was
obtained per culture sample. Complementary DNA (cDNA) synthesis was the first step of the two-step
quantitative reverse transcriptase Polymerase Chain Reaction (RT-qPCR). cDNA was generated by the
enzyme reverse transcriptase (RT). 1000 ng of total RNA was used to synthesize cDNA according to the
manufacture instruction of iScript™ cDNA Synthesis Kit. Used primers are listed in supplementary
Table S3.
Additionally, we investigated the peptide-induced changes in transcription level of genes related
to biofilm formation. Expression of hyphal-specific and biofilm-associated genes: agglutinin-like
protein precursor 3 (ALS3) and their transcriptional regulators (CYR1 and EFG1) was analyzed.
In addition, genes related to the production of extracellular matrix (ADH5, CSH1, GSC1 and ZAP1)
were evaluated. C. albicans cells (OD592 ~0.4) were grown in the absence or presence of 10 µM of each
peptide in 6-well plates for 24 h at 37 ◦C. Next, wells were washed with PBS and adhered cells were
removed from the bottom of the wells by scraping. Total RNA was extracted from sessile cells, as
described above, and stored at −80 ◦C. The quality and quantity of the extracted RNA were determined
spectrophotometrically. The cDNA library from the total RNA extract (100 ng) was build using the
Reverse Transcription System kit (Promega), following manufacturer’s instructions.
Gene expression level was quantified by Real Time Quantitative Polymerase Chain Reaction
(RT-qPCR). For each reaction, 1µL of cDNA (10 to 50 ng) was mixed with 2 µL of free RNase water,
5 µL of iTaq Universal Master SYBR Green Supermix and 1 µL of each primer of interest (500 nM) in a
total volume of 10 µL. Reactions were incubated at 60 ◦C for 1 min and 95 ◦C for 10 min, followed by
40 cycles of 95 ◦C for 15 s and 60 ◦C for 1 min. All the primers used for RT-qPCR were from Bio-Rad.
ACTIN was used as a housekeeping gene for data normalization. All the primers used for RT-qPCR
were from Bio-Rad. Data analysis was performed using Bio-Rad CFX Manager. Three independent
experiments were performed, with their own technical triplicate. The figures of gene level expression
were designed by Graphpad Prism6 software.
4.12. Biofilm Growth
Biofilms of C. albicans were prepared on pre-sterilized, polystyrene, flat bottomed 96-well microtiter
plates following a modification of a previously described protocol [85,86]. First, a standardized yeast
suspension (107 cells/mL) of C. albicans was prepared by suspending colonies from 12 h-old culture in
RPMI-1640 medium and adjusted to an optical density of 0.4 at 520 nm. 100 µL of yeast suspension was
dispensed into each well of microtiter plate using a multichannel pipette and the plates were incubated
at 37 ◦C for 90 min to allow adherence of yeast on the surface of each well. After the adhesion phase,
the non-adherent cells were removed, and each well was washed twice with 150 µL PBS. An aliquot of
100 µL of RPMI 1640 medium was transferred to each washed well and the plates were incubated at
37 ◦C for 24 h to allow biofilm formation.
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4.13. Biofilm Viability Test
Following the biofilm formation phase, the medium was aspirated, and each well was gently
washed twice with 200 µL of PBS to remove non-adherent cells. 200 µL of each peptide with
concentrations ranging from 5, 10 and 20 times of the determined MFC were added to the respective
wells and the plates were incubated as described above for 24 h. Colistin and amphotericin B were
assayed as positive controls of inhibition. Wells with biofilm and media alone and biofilm-free wells
were included as positive and background references. After treatment with the peptides, the medium
was removed, and each well was washed twice with 200 µL PBS and 90 µL of RPMI-1640 medium were
added. Then, 10 µL of PrestoBlueTM was added to prewashed biofilm and control wells and incubated
for 10 min in the dark. Changes in the fluorescence signal were quantified at excitation/emission of
535–615 nm using a 96-well plate reader (Victor3, Perkin-Elmer, Waltham, MA, USA).
4.14. Biofilm Mass Eradication
Biofilm mass eradication was quantified by the crystal violet staining assay according to [85,87],
with slight modifications. Briefly, the biofilm- coated wells of microtiter plates were washed twice
with 200 µL of PBS and then air-dried for 45 min. Then, each of the washed wells was stained with
100 µL of 0.4% aqueous crystal violet solution for 45 min. Afterwards, each well was washed four
times with 350 µL of distilled water and immediately destained with 200 µL of 96% ethanol. After
45 min of destaining, 100 µL of destaining solution was transferred to a new well and the amount of
the crystal violet was measured with a microtiter plate reader Victor3 at 570 nm.
4.15. Confocal Microscopy
Biofilms were visualized by confocal microscopy following Live/Dead staining (Molecular Probes,
Eugene, OR, USA). Overnight culture of C. albicans cells were centrifuged at 5000× g for 5 min, washed,
resuspended in fresh RPMI-1640 medium and adjusted to an OD592 of 0.4. The candidal suspension
was added to a plate coverslip system 35-cm2 and incubated at 37 ◦C for 24 h. At 24 h, C. albicans cells
were washed three times with PBS and incubated during 4h with 20 µM of each peptide resuspended
in HEPES 10 mM pH 7.5 at 37 ◦C. After incubation, the wells were washed three times with PBS to
remove planktonic C. albicans cells. Then, the biofilms were prestained using the SYTO9/propidium
iodide 1:1 mixture provided by the Live/Dead staining kit and incubated in the dark at 37 ◦C for 15 min.
Changes were imaged using a laser scanning confocal microscope (Olympus FluoView 1000 equipped
with a UPlansApo 60× lens in 1.4 oil immersion objective, UK). Mortality was calculated as the mean
area of 10 randomly selected fields and quantified using ImageJ software (Oxford Instruments, Zurich,
Switzerland). Unspecific background was subtracted, and particles with a diameter larger than 4 µm
were analyzed. Biofilm three-dimensional reconstruction and estimation of the biofilm depth were
performed with the IMARIS Bitplane imaging software.
4.16. Cytotoxicity Assay
The peptide cytoxicity was evaluated using the human monocytic THP1 cell line. The assay was
performed in 96-well cell culture flat-bottom plates (Costar; Appleton Woods) in triplicate. THP-1
cultures were induced to macrophages by adding 2 ng/mL of colony-stimulating factor (R&D Systems,
Germany). Peptides were serially diluted from 50 to 0.1 µM and added to 5 × 105 cells/mL. After
48 h of incubation, the cells were washed twice with 1× PBS, and fresh RPMI-1640 complete medium
was added. Plates were then treated with 30 µL of a freshly prepared 0.01% resazurin solution and
incubated overnight at 37 ◦C. The following day the change in color was observed and the fluorescence
intensity was measured (λex560 nm, λem590 nm). The 50% growth inhibitory concentration (GIC50)
was determined based on the resazurin fluorescence signal.
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4.17. Statistical Analysis
Statistical analysis was performed using Prism6® by one-way ANOVA test followed by Dunnett’s
Multiple Comparison Test. The results were from three independent experiments. A p value < 0.05
and p < 0.001 were considered statistically significant.
5. Conclusions
We can conclude that the pleiotropic antimicrobial mechanism of action of the hRNase-derived
peptides offers multiple advantages to be considered. Results highlight RN3 as a promising lead
peptide for the development of novel antifungal agents. In particular, the peptide combines potent
killing activity on planktonic C. albicans by cell binding and membrane permeabilization, together
with the ability to agglutinate cells, inhibit biofilm formation and eradicate the mature stablished
communities at low micromolar concentrations. Therefore, hRNases derived peptides are proposed as
suitable candidates to develop novel and safe antifungal agents.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/18/
4558/s1.
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Abbreviations
CFU Colony forming units
EDTA Ethylenediaminetetraacetic acid
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis
ATP Adenosine triphosphate
DiSC3 3,3′-Dipropylthiadicarbocyanine Iodide
IC Inhibition Concentration
MFC Minimum Fungicidal Concentration
MAC Minimum Agglutination Concentration
PI Propidium iodide
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